Inotropes and inodilators for acute heart failure: Sarcomere active drugs in focus

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 3, 2014, Pages 199-208

  Nagy, László ^a   Pollesello, Piero ^a   Papp, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Acute heart failure syndrome; Ca2+ mobilizer; Levosimendan; Omecamtiv mecarbil; Sarcomere targeted agent

Indexed keywords

CALCIUM; CALCIUM SENSITIZER; CARDIOVASCULAR AGENT; INODILATOR; INOTROPIC AGENT; LEVOSIMENDAN; MYOSIN; OMECAMTIV MECARBIL; PIMOBENDAN; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; VASODILATOR AGENT;

ACUTE HEART FAILURE; ARTICLE; CALCIUM TRANSPORT; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG INDICATION; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HUMAN; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SARCOMERE; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION; ACUTE DISEASE; ANIMAL; HEART FAILURE; HEART MUSCLE CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACUTE DISEASE; ANIMALS; CALCIUM; CARDIOTONIC AGENTS; HEART FAILURE; HUMANS; MOLECULAR TARGETED THERAPY; MYOCYTES, CARDIAC; OXYGEN CONSUMPTION; SARCOMERES; VASODILATOR AGENTS;

EID: 84906070649     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000113     Document Type: Article

References (107)

1. Felker GM, Adams KF Jr, Konstam MA, et al. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J. 2003; 145(suppl 2): S18-S25.
2. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005; 112: 3958-3968.
3. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33: 1787-1847.
4. Givertz MM, Teerlink JR, Albert NM, et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail. 2013; 19: 371-389.
5. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991; 325: 1468-1475.
6. Cotter G, Felker GM, Adams KF, et al. The pathophysiology of acute heart failure-is it all about fluid accumulation? Am Heart J. 2008; 155: 9-18.
7. Cotter G, Moshkovitz Y, Milovanov O, et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail. 2002; 4: 227-234.
8. Lee JA, Allen DG. Calcium sensitisers: mechanisms of action and potential usefulness as inotropes. Cardiovasc Res. 1997; 36: 10-20.
9. Katz AM. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation. 1986; 73(3 pt 2): III184-III190.
10. Petersen JW, Felker GM. Inotropes in the management of acute heart failure. Crit Care Med. 2008; 36(suppl 1): S106-S111.
11. 2+ sensitizers. Circ J. 2008; 72: 1915-1925.
12. Schwartz A, Whitmer K, Grupp G, et al. Mechanism of action of digitalis: is the Na, K-ATPase the pharmacological receptor? Ann N Y Acad Sci. 1982; 402: 253-271.
13. Digitalis Investigation G. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336: 525-533.
14. Ahmed A, Bourge RC, Fonarow GC, et al. Digoxin use and lower 30-day all-cause readmission for medicare beneficiaries hospitalized for heart failure. Am J Med. 2014; 127: 61-70.
15. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999; 138(1 pt 1): 78-86.
16. Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol. 2009; 4: 2013-2026.
17. Al-Hesayen A, Parker JD. The effects of dobutamine on renal sympathetic activity in human heart failure. J Cardiovasc Pharmacol. 2008; 51: 434-436.
18. Metra M, Nodari S, Parrinello G, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008; 10: 188-195.
19. Cuffe MS, Califf RM, Adams KF Jr, et al, Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure I. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-1547.
20. Ferrandi M, Barassi P, Tadini-Buoninsegni F, et al. Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition. Br J Pharmacol. 2013; 169: 1849-1861.
21. Shah SJ, Blair JE, Filippatos GS, et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am Heart J. 2009; 157: 1035-1041.
22. 2+ cycling. Circ Res. 2007; 100: 96-104.
23. Perrone SV, Kaplinsky EJ. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure. Int J Cardiol. 2005; 103: 248-255.
24. Nieminen MS, Pollesello P, Vajda G, et al. Effects of levosimendan on the energy balance: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2009; 53: 302-310.
25. Solaro RJ, Ruegg JC. Stimulation of Ca++ binding and ATPase activity of dog cardiac myofibrils by AR-L 115BS, a novel cardiotonic agent. Circ Res. 1982; 51: 290-294.
26. Parsons WJ, Ramkumar V, Stiles GL. The new cardiotonic agent sulmazole is an A1 adenosine receptor antagonist and functionally blocks the inhibitory regulator, Gi. Mol Pharmacol. 1988; 33: 441-448.
27. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation. 2006; 113: 305-315.
28. Kooij V, Zhang P, Piersma SR, et al. PKCalpha-specific phosphorylation of the troponin complex in human myocardium: a functional and proteomics analysis. PLoS One. 2013; 8: e74847.
29. Haikala H, Linden IB. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol. 1995; 26 (suppl 1): S10-S19.
30. Solaro RJ, Gambassi G, Warshaw DM, et al. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res. 1993; 73: 981-990.
31. 2+ -sensitizers in permeabilized cardiac myocytes from donor and end-stage failing human hearts. J Muscle Res Cell Motil. 2004; 25: 219-224.
32. Papp Z, Edes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012; 159: 82-87.
33. Gomes AV, Potter JD, Szczesna-Cordary D. The role of troponins in muscle contraction. IUBMB Life. 2002; 54: 323-333.
34. Parmacek MS, Leiden JM. Structure, function, and regulation of troponin C. Circulation. 1991; 84: 991-1003.
35. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c. Mol Cell Biochem. 2004; 266: 87-107.
36. 2+-sensitizers that target the cardiac troponin complex. J Mol Cell Cardiol. 2010; 49: 1031-1041.
37. 2+-sensitization. Eur J Pharmacol. 2004; 486: 1-8.
38. 2+]i in guinea-pig isolated ventricular myocytes. Eur J Pharmacol. 1997; 339: 97-100.
39. Hajjar RJ, Schmidt U, Helm P, et al. Ca++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther. 1997; 280: 247-254.
40. Haikala H, Kaivola J, Nissinen E, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995; 27: 1859-1866.
41. Janssen PM, Datz N, Zeitz O, et al. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol. 2000; 404: 191-199.
42. Szilagyi S, Pollesello P, Levijoki J, et al. Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone. J Cardiovasc Pharmacol. 2005; 46: 369-376.
43. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res. 1995; 77: 107-113.
44. Haikala H, Kaheinen P, Levijoki J, et al. The role of cAMP- and cGMPdependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res. 1997; 34: 536-546.
45. Szilagyi S, Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol. 2004; 486: 67-74.
46. Erdei N, Papp Z, Pollesello P, et al. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol. 2006; 148: 696-702.
47. Hohn J, Pataricza J, Petri A, et al. Levosimendan interacts with potassium channel blockers in human saphenous veins. Basic Clin Pharmacol Toxicol. 2004; 94: 271-273.
48. Kaheinen P, Pollesello P, Levijoki J, et al. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 2001; 37: 367-374.
49. Rieg AD, Rossaint R, Verjans E, et al. Levosimendan relaxes pulmonary arteries and veins in precision-cut lung slices-the role of K-channels, cAMP and cGMP. PLoS One. 2013; 8: e66195.
50. Yildiz O. Vasodilating mechanisms of levosimendan: involvement of K+ channels. J Pharmacol Sci. 2007; 104: 1-5.
51. 2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997; 333: 249-259.
52. Yokoshiki H, Sperelakis N. Vasodilating mechanisms of levosimendan. Cardiovasc Drugs Ther. 2003; 17: 111-113.
53. Godeny I, Pollesello P, Edes I, et al. Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo. Pharmacol Rep. 2013; 65: 1304-1310.
54. Leather HA, Ver Eycken K, Segers P, et al. Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigs. Crit Care Med. 2003; 31: 2339-2343.
55. Sonntag S, Sundberg S, Lehtonen LA, et al. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004; 43: 2177-2182.
56. Grossini E, Molinari C, Pollesello P, et al. Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther. 2012; 342: 376-388.
57. Jensen H, Eija R, Tuomas M, et al. Levosimendan decreases intracranial pressure after hypothermic circulatory arrest in a porcine model. Scand Cardiovasc J. 2011; 45: 307-315.
58. Grossini E, Pollesello P, Bellofatto K, et al. Protective effects elicited by levosimendan against liver ischemia/reperfusion injury in anesthetized rats. Liver Transpl. 2013.
59. Schwarte LA, Picker O, Bornstein SR, et al. Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs. Crit Care Med. 2005; 33: 135-142.
60. Pinto BB, Rehberg S, Ertmer C, et al. Role of levosimendan in sepsis and septic shock. Curr Opin Anaesthesiol. 2008; 21: 168-177.
61. Sareila O, Korhonen R, Auvinen H, et al. Effects of levo- and dextrosimendan on NF-kappaB-mediated transcription, iNOS expression and NO production in response to inflammatory stimuli. Br J Pharmacol. 2008; 155: 884-895.
62. Revermann M, Schloss M, Mieth A, et al. Levosimendan attenuates pulmonary vascular remodeling. Intensive Care Med. 2011; 37: 1368-1377.
63. Hasslacher J, Bijuklic K, Bertocchi C, et al. Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study. Crit Care. 2011; 15: R166.
64. Segreti JA, Marsh KC, Polakowski JS, et al. Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1, 4, 5, 6-tetrahydropyridazin-3-yl)phenyl) acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4, 5-dihydropyridazin- 3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure. J Pharmacol Exp Ther. 2008; 325: 331-340.
65. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol. 2004; 68: 807-812.
66. du Toit EF, Genis A, Opie LH, et al. A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol. 2008; 154: 41-50.
67. Facundo HT, Fornazari M, Kowaltowski AJ. Tissue protection mediated by mitochondrial K+ channels. Biochim Biophys Acta. 2006; 1762: 202-212.
68. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc Res. 2004; 61: 372-385.
69. Honisch A, Theuring N, Ebner B, et al. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition. Basic Res Cardiol. 2010; 105: 155-167.
70. Markou T, Makridou Z, Galatou E, et al. Multiple signalling pathways underlie the protective effect of levosimendan in cardiac myocytes. Eur J Pharmacol. 2011; 667: 298-305.
71. Soeding PF, Crack PJ, Wright CE, et al. Levosimendan preserves the contractile responsiveness of hypoxic human myocardium via mitochondrial K(ATP) channel and potential pERK 1/2 activation. Eur J Pharmacol. 2011; 655: 59-66.
72. Grossini E, Molinari C, Caimmi PP, et al. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel. Br J Pharmacol. 2009; 156: 250-261.
73. Caimmi PP, Molinari C, Uberti F, et al. Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide. Eur J Cardiothorac Surg. 2011; 39: e59-67.
74. Levijoki J, Pollesello P, Kaheinen P, et al. Improved survival with simendan after experimental myocardial infarction in rats. Eur J Pharmacol. 2001; 419: 243-248.
75. Lepran I, Pollesello P, Vajda S, et al. Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model. J Cardiovasc Pharmacol. 2006; 48: 148-152.
76. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2007; 50: 257-263.
77. Pathak A, Lebrin M, Vaccaro A, et al. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. J Clin Pharm Ther. 2013; 38: 341-349.
78. Landoni G, Mizzi A, Biondi-Zoccai G, et al. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiol. 2010; 76: 276-286.
79. Landoni G, Mizzi A, Biondi-Zoccai G, et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2010; 24: 51-57.
80. Bohm M, Morano I, Pieske B, et al. Contribution of cAMPphosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res. 1991; 68: 689-701.
81. Takahashi R, Shimazaki Y, Endoh M. Decrease in Ca(2+)-sensitizing effect of UD-CG 212 Cl, a metabolite of pimobendan, under acidotic condition in canine ventricular myocardium. J Pharmacol Exp Ther. 2001; 298: 1060-1066.
82. Lynch JJ Jr, Uprichard AC, Frye JW, et al. Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction. J Cardiovasc Pharmacol. 1989; 14: 585-597.
83. Tissier R, Chetboul V, Moraillon R, et al. Increased mitral valve regurgitation and myocardial hypertrophy in two dogs with long-term pimobendan therapy. Cardiovasc Toxicol. 2005; 5: 43-51.
84. Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the pimobendan in congestive heart failure (PICO) trial. Heart. 1996; 76: 223-231.
85. Bers DM, Harris SP. Translational medicine: to the rescue of the failing heart. Nature. 2011; 473: 36-39.
86. Malik FI, Morgan BP. Cardiac myosin activation part 1: from concept to clinic. J Mol Cell Cardiol. 2011; 51: 454-461.
87. Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011; 331: 1439-1443.
88. Teerlink JR. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev. 2009; 14: 289-298.
89. Shen YT, Malik FI, Zhao X, et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail. 2010; 3: 522-527.
90. Dickstein K. Cardiac myosin activation: will theory and practice coincide? Lancet. 2011; 378: 639-641.
91. Meijs MF, Asselbergs FW, Doevendans PA. Omecamtiv mecarbil: a promising new drug in systolic heart failure. Eur J Heart Fail. 2012; 14: 232-233.
92. Teerlink JR, Clarke CP, Saikali KG, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011; 378: 667-675.
93. Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, doseranging phase 2 trial. Lancet. 2011; 378: 676-683.
94. Teerlink JRFM, McMurray JJ, Ponikowski P, et al. Study to evaluate the safety and efficacy of IV infusion treatment with omecamtiv mecarbil in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure (ATOMIC-AHF), 2013. Available at: www. clinicaltrials.gov, identifier: NCT01300013. Accessed April 20, 2014.
95. Valentova M, von Haehling S. An overview of recent developments in the treatment of heart failure: update from the ESC congress 2013. Expert Opin Investig Drugs. 2014; 23: 573-578.
96. Garg V, Frishman WH. A new approach to inotropic therapy in the treatment of heart failure: cardiac myosin activators in treatment of HF. Cardiol Rev. 2013; 21: 155-159.
97. Howlett SE. Searching for the ideal inotropic agent to rescue a failing heart. Cardiovasc Res. 2011; 91: 371-372.
98. 2+ entry blocker: SR 33805. Eur J Pharmacol. 1993; 246: 181-193.
99. Bokenes J, Aronsen JM, Birkeland JA, et al. Slow contractions characterize failing rat hearts. Basic Res Cardiol. 2008; 103: 328-344.
100. Ait Mou Y, Toth A, Cassan C, et al. Beneficial effects of SR33805 in failing myocardium. Cardiovasc Res. 2011; 91: 412-419.
101. 2+ -sensitizing properties in cardiac myocytes. Br J Pharmacol. 2003; 139: 99-108.
102. Paolocci N, Katori T, Champion HC, et al. Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from betaadrenergic signaling. Proc Natl Acad Sci U S A. 2003; 100: 5537-5542.
103. Sabbah HN, Tocchetti CG, Wang M, et al. Nitroxyl (HNO): a novel approach for the acute treatment of heart failure. Circ Heart Fail. 2013; 6: 1250-1258.
104. Dai T, Tian Y, Tocchetti CG, et al. Nitroxyl increases force development in rat cardiac muscle. J Physiol. 2007; 580(pt 3): 951-960.
105. Gao WD, Murray CI, Tian Y, et al. Nitroxyl-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function. Circ Res. 2012; 111: 1002-1011.
106. Sivakumaran V, Stanley BA, Tocchetti CG, et al. HNO enhances SERCA2a activity and cardiomyocyte function by promoting redoxdependent phospholamban oligomerization. Antioxid Redox Signal. 2013; 19: 1185-1197.
107. 2+-cycling. Front Biosci (Elite Ed). 2010; 2: 614-626.